FOR IMMEDIATE RELEASE Compugen Reports Third Quarter 2025 Results Exhibit 99.1 HOLON, ISRAEL, November 10, 2025 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial results for the third quarter of 2025 and provided a corporate update. "I am thrilled to lead Compugen as our strong fundamentals and differentiated science gain clinical momentum," said Eran Ophir, Ph.D., Pr ...